title: [Conditions of "thymidine analog mutations" (TAMs) in naive patients treated with different combinations of d4T].
abstract: Recently, d4T/ddI combination has been associated with the selection of thymidine analogue mutations (TAMs) in 50% of patients with a detectable viral load after 6 to 12 months of this bi-therapy (ALBI, STADI and BMS A1460 tests). We evaluated the rate of selection of the TAMs in naive patients with a viral load of > 200 copies/mL after: 6 months to 1 year of d4T/3TC bi-therapy (group 1); 1 year or more of a treatment including d4T/3TC (group 2); and more than 6 months of tri-therapy including d4T/ddI (group 3). The reverse transcriptase gene has ben studied in 33 patients in group 1, 17 patients in group 2 and ten patients in group 3. For the latter patients, the tri-therapies were as follows: d4T/ddI/PI (n = 5), d4T/ddI/NNRTI (n = 4), d4T/ddI/NRTI (n = 1). For the group 1 patients, at baseline, two patients already had TAMs. At M6, all the patients acquired the 3TC-associated mutations, M184V. Only one patient selected a MDR mutation profile (F116Y, Q151M). At M12, 26 of 33 plasmas were analysed. Only one patient selected one TAM (T215Y). For the group 2 patients, only three patients selected TAMs after more than 30 months of treatment. For the group 3 patients, at baseline, only one patient already harbored TAMs. None of the other patients had selected TAMs. In patients who received d4T/ddI/3TC, only the M184V, the 3TC-associated mutation, was selected. In conclusion, stavudine in association with 3TC selected a low rate of TAMs; in patients receiving a treatment including d4T/3TC, time of exposure to stavudine seemed to be an important parameter for the selection of TAMs; and in contrast to results obtained on d4T/ddI, tri-therapies including d4T/ddI did not select any TAMs, whatever the combination (NRTI, NNRTI, PI).
authors.affiliation: Laboratoire de virologie, hôpital Pitié-Salpêtrière, Paris, France.
authors.forename: M
authors.initials: M
authors.lastname: Mouroux
authors.forename: J
authors.initials: J
authors.lastname: Izopet
authors.forename: D
authors.initials: D
authors.lastname: Descamps
authors.forename: C
authors.initials: C
authors.lastname: Delaugerre
authors.forename: A
authors.initials: A
authors.lastname: Yvon-Groussin
authors.forename: F
authors.initials: F
authors.lastname: Angleraud
authors.forename: A
authors.initials: A
authors.lastname: Coutellier
authors.forename: M
authors.initials: M
authors.lastname: Bonmarchand
authors.forename: M A
authors.initials: MA
authors.lastname: Valantin
authors.forename: S
authors.initials: S
authors.lastname: Matheron
authors.forename: H
authors.initials: H
authors.lastname: Agut
authors.forename: C
authors.initials: C
authors.lastname: Katlama
authors.forename: F
authors.initials: F
authors.lastname: Brun-Vezinet
authors.forename: V
authors.initials: V
authors.lastname: Calvez
mesh_terms: D019380:Anti-HIV Agents / Q000627:therapeutic use; D004351:Drug Resistance / Q000235:genetics*; D006801:Humans; D019259:Lamivudine / Q000627:therapeutic use; D009154:Mutation; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use*; D018119:Stavudine / Q000627:therapeutic use*; D013936:Thymidine / Q000031:analogs & derivatives*; D015215:Zidovudine / Q000627:therapeutic use
chemical_list: D019380:Anti-HIV Agents; D018894:Reverse Transcriptase Inhibitors; D019259:Lamivudine; D015215:Zidovudine; D018119:Stavudine; D013936:Thymidine